Reasons Why MannKind Could Succeed Where Pfizer Failed. bUT pfizer and mannkind are on speaking terms again.
Long-time MannKind (NASDAQ:MNKD) bears have been yelling for years that inhaled insulin is simply a losing idea. After all, healthcare giant Pfizer (NYSE:PFE) tried to launch the world's first inhaled insulin, Exubera, almost 9 years ago, and ended up pulling the plug in less than a year after disappointing sales.
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant. And investors thinks cooperation is on the way.